1 approved for marketing, 1 completed, 1 enrolling by invitation, 1 recruiting. 2 Phase 1, 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Enrolling by invitation 1 |
Follow Angiotensin I: new trials by email Literature Review of Angiotensin I trials Research Report on Angiotensin I
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension Angiotensin-II - Vasodilatory Shock | Phase 4 | Enrolling by invitation | Northwell Health | 30 | 2025-10-28 | 2026-10-23 |
| A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock LJPC-501 (angiotensin II), Placebo - Catecholamine-resistant Hypotension (CRH), Distributive Shock | Phase 2 | Unknown | La Jolla Pharmaceutical Company | 100 | 2018-08-01 | 2018-08-09 |
| A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension LJPC-501, Placebo - Catecholamine-resistant Hypotension (CRH), Distributive Shock | Phase 3 | Completed | La Jolla Pharmaceutical Company | 344 | 2015-03-01 | 2018-03-27 |
| A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome LJPC-501 - Hepatorenal Syndrome Type I and Type II | Phase 1 | Terminated | La Jolla Pharmaceutical Company | 6 | 2014-03-01 | 2016-03-03 |
| : Vascular Function in Health and Disease Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123 - Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension | Phase 1 | Recruiting | D. Walter Wray | 420 | 2008-09-01 | 2026-09-25 |
| Expanded Access for LJPC-501 LJPC-501 - Catecholamine Resistant Hypotension (CRH), Distributive Shock | Approved for marketing | La Jolla Pharmaceutical Company | 2018-03-08 |
Sepsis (2) · Familial Primary Pulmonary Hypertension (1) · Heart Failure (1) · Hepatorenal Syndrome (1) · Hypertension (1) · Pulmonary Disease, Chronic Obstructive (1) · Shock, Septic (1)
La Jolla Pharmaceutical Company (4) · D. Walter Wray (1) · Northwell Health (1)
United States (4) · Belgium (2) · Australia (1) · Canada (1) · Finland (1) · France (1) · Germany (1) · Lithuania (1) · New Zealand (1) · Switzerland (1) · United Kingdom (1)
David W Wray, Ph.D. (1) · George F Tidmarsh, MD, PhD (1) · George Tidmarsh, MD, PhD (1)
PMID 26931475, PMID 28528561, PMID 30144016, PMID 32028998, PMID 32609011, PMID 37147690, PMID 38103056, PMID 38637829, PMID 39972379